Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes - MaaT Pharma

Download the poster

Previous PostPooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
Next PostNovember 8, 2022: MaaT Pharma Reports Cash and Revenues for Third Quarter 2022

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club